Reviewing ImmuCell (ICCC) & Oxford Immunotec Global (OXFD)

ImmuCell (NASDAQ:ICCC) and Oxford Immunotec Global (NASDAQ:OXFD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, profitability, risk and earnings.

Profitability

This table compares ImmuCell and Oxford Immunotec Global’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ImmuCell -14.07% -4.36% -3.02%
Oxford Immunotec Global -23.41% -39.85% -23.41%

Valuation and Earnings

This table compares ImmuCell and Oxford Immunotec Global’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ImmuCell $10.43 million 4.01 -$160,000.00 N/A N/A
Oxford Immunotec Global $103.08 million 3.98 -$32.88 million ($1.36) -11.63

ImmuCell has higher earnings, but lower revenue than Oxford Immunotec Global.

Volatility and Risk

ImmuCell has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500. Comparatively, Oxford Immunotec Global has a beta of -0.09, indicating that its share price is 109% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for ImmuCell and Oxford Immunotec Global, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ImmuCell 0 0 0 0 N/A
Oxford Immunotec Global 0 0 2 0 3.00

Oxford Immunotec Global has a consensus price target of $17.00, indicating a potential upside of 7.53%. Given Oxford Immunotec Global’s higher possible upside, analysts clearly believe Oxford Immunotec Global is more favorable than ImmuCell.

Insider & Institutional Ownership

13.7% of ImmuCell shares are held by institutional investors. Comparatively, 92.4% of Oxford Immunotec Global shares are held by institutional investors. 17.7% of ImmuCell shares are held by insiders. Comparatively, 6.6% of Oxford Immunotec Global shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

ImmuCell beats Oxford Immunotec Global on 7 of the 11 factors compared between the two stocks.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company primarily offers First Defense, an orally delivered scours preventive product for newborn calves. It also provides California Mastitis Test, which is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic. In addition, the company is involved in developing purified Nisin treatment for subclinical mastitis in lactating dairy cows; and selling various product applications of its First Defense Technology, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products to animal health distributors, fleet stores, and direct to farms. The company was founded in 1982 and is headquartered in Portland, Maine.

About Oxford Immunotec Global

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology. The company develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. It develops and markets T-SPOT.TB test used to test for tuberculosis. The company is also developing a range of assays for tick-borne diseases, such as lyme disease, as well as for use in screening blood for the parasite babesia microti that causes babesiosis; and T-SPOT.CMV test that measures the strength of a patient's cellular response to CMV infection. Oxford Immunotec Global PLC markets its T-SPOT.TB test through a direct sales force in the United States, certain European countries, and Japan, as well as through distributors in other parts of the world. Oxford Immunotec Global PLC was founded in 2002 and is headquartered in Abingdon, the United Kingdom.

Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply